Toronto Dominion Bank Buys 3,117 Shares of Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank increased its position in shares of Insulet Co. (NASDAQ:PODD) by 15.3% during the 3rd quarter, Holdings Channel reports. The fund owned 23,502 shares of the medical instruments supplier’s stock after buying an additional 3,117 shares during the quarter. Toronto Dominion Bank’s holdings in Insulet were worth $5,470,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. raised its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC bought a new stake in shares of Insulet in the 2nd quarter valued at $32,000. Venturi Wealth Management LLC raised its stake in Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. lifted its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in Insulet in the second quarter valued at about $52,000.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.47% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

PODD has been the subject of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays raised their price objective on shares of Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Citigroup lifted their price target on Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley upped their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.44.

Insulet Stock Down 0.9 %

NASDAQ:PODD opened at $269.34 on Friday. The firm has a market capitalization of $18.89 billion, a price-to-earnings ratio of 46.12, a price-to-earnings-growth ratio of 4.18 and a beta of 1.21. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.77. The stock’s 50 day moving average price is $251.37 and its two-hundred day moving average price is $220.31.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.